肾复康胶囊联合利妥昔单抗治疗膜性肾病的效果及对M型磷脂酶A2受体表达的影响

Effect of Shenfukang capsule combined with rituximab in the treatment of membranous nephropathy and its influence on the expression of M-type phospholipase A2 receptor

目的探讨肾复康胶囊联合利妥昔单抗治疗膜性肾病(MN)的效果及对M型磷脂酶A2受体(PLA2R)表达的影响。方法选择2019年7月至2021年3月收治的70例MN患者,以随机数字表法将其分为对照组与观察组,各35例。对照组采用常规治疗+利妥昔单抗,观察组在对照组治疗基础上加用肾复康胶囊。比较两组的治疗效果。结果治疗后,观察组的24 h尿蛋白定量(24 h UP)、血肌酐(Scr)水平低于对照组,白蛋白(ALB)水平及估算肾小球滤过率(eGFR)高于对照组(P<0.05)。治疗后,观察组的超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、白细胞介素-1(IL-1)水平低于对照组,白细胞介素-10(IL-10)水平高于对照组(P<0.05)。治疗后,观察组的PLA2R抗原、PLA2R抗体阳性率低于对照组(P<0.05)。结论肾复康胶囊联合利妥昔单抗治疗MN的效果满意,可减轻微炎症状态,调节PLA2R抗原和PLA2R抗体表达。

Objective To explore the effect of Shenfukang capsule combined with rituximab in the treatment of membranous nephropathy(MN)and its influence on the expression of M-type phospholipase A2 receptor(PLA2R).Methods A total of 70 patients with MN admitted from July 2019 to March 2021 were selected and divided into control group and observation group by random number table method,with 35 cases in each group.The control group was treated with conventional therapy+rituximab,and the observation group was treated with Shenfukang capsule on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the levels of 24 h urine protein(24 h UP)and serum creatinine(Scr)level in the observation group were lower than those in the control group,and the albumin(ALB)level and estimated glomerular filtration rate(e GFR)were higher than those in the control group(P<0.05).After treatment,high sensitivity C-reactive protein(hs-CRP),procalcitonin(PCT)and interleukin-1(IL-1)in the observation group were lower than those in the control group,and the level of interleukin-10(IL-10)was higher than that in the control group(P<0.05).After treatment,the positive rates of PLA2R antigen and PLA2R antibody in the observation group were lower than those in the control group(P<0.05).Conclusion Shenfukang capsule combined with rituximab in the treatment of MN has a satisfactory effect.It can reduce micro-inflammatory state and regulate the expression of PLA2R antigen and PLA2R antibody.